Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ktta · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.00
Consensus
$3.00
+421.2% upside
Low
$3.00
Median: $3 · Last Close: $0.58
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.55 | ↓ 5.00% |
1-day model range: $0.53–$0.56. Peak: $0.56 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · KTTA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-09 | EF Hutton | Maintains | Buy→Buy |
| 2023-04-02 | EF Hutton | Maintains | Buy→Buy |
| 2021-12-14 | EF Hutton | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Pasithea Therapeutics Corp. (KTTA) stock. Of the recent 4 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover KTTA.
Analyst Recommendation Trends
KTTA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-1.50
EPS Next Year
$-1.50
↑ 0.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast KTTA EPS of $-1.50 for the current fiscal year, based on estimates from 1 analysts. The KTTA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KTTA stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KTTA price target is $3.00 (+421.2% upside), with an analyst consensus of Buy.
The KTTA short-term stock prediction for tomorrow is $0.55 (-5.00%).
Pasithea Therapeutics Corp. trades on NASDAQ under the ticker KTTA. The KTTA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
KTTA forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month KTTA price target is $3.00, with a high forecast of $3.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +421.2% potential upside from the current price of $0.58.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.